403 related articles for article (PubMed ID: 21655080)
1. DNA ligase III promotes alternative nonhomologous end-joining during chromosomal translocation formation.
Simsek D; Brunet E; Wong SY; Katyal S; Gao Y; McKinnon PJ; Lou J; Zhang L; Li J; Rebar EJ; Gregory PD; Holmes MC; Jasin M
PLoS Genet; 2011 Jun; 7(6):e1002080. PubMed ID: 21655080
[TBL] [Abstract][Full Text] [Related]
2. Alternative end-joining is suppressed by the canonical NHEJ component Xrcc4-ligase IV during chromosomal translocation formation.
Simsek D; Jasin M
Nat Struct Mol Biol; 2010 Apr; 17(4):410-6. PubMed ID: 20208544
[TBL] [Abstract][Full Text] [Related]
3. Ligase I and ligase III mediate the DNA double-strand break ligation in alternative end-joining.
Lu G; Duan J; Shu S; Wang X; Gao L; Guo J; Zhang Y
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1256-60. PubMed ID: 26787905
[TBL] [Abstract][Full Text] [Related]
4. Marked contribution of alternative end-joining to chromosome-translocation-formation by stochastically induced DNA double-strand-breaks in G2-phase human cells.
Soni A; Siemann M; Pantelias GE; Iliakis G
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():2-8. PubMed ID: 26520366
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal translocations in human cells are generated by canonical nonhomologous end-joining.
Ghezraoui H; Piganeau M; Renouf B; Renaud JB; Sallmyr A; Ruis B; Oh S; Tomkinson AE; Hendrickson EA; Giovannangeli C; Jasin M; Brunet E
Mol Cell; 2014 Sep; 55(6):829-842. PubMed ID: 25201414
[TBL] [Abstract][Full Text] [Related]
6. Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining.
Soni A; Siemann M; Grabos M; Murmann T; Pantelias GE; Iliakis G
Nucleic Acids Res; 2014 Jun; 42(10):6380-92. PubMed ID: 24748665
[TBL] [Abstract][Full Text] [Related]
7. Crucial role for DNA ligase III in mitochondria but not in Xrcc1-dependent repair.
Simsek D; Furda A; Gao Y; Artus J; Brunet E; Hadjantonakis AK; Van Houten B; Shuman S; McKinnon PJ; Jasin M
Nature; 2011 Mar; 471(7337):245-8. PubMed ID: 21390132
[TBL] [Abstract][Full Text] [Related]
8. DNA ligase III is critical for mtDNA integrity but not Xrcc1-mediated nuclear DNA repair.
Gao Y; Katyal S; Lee Y; Zhao J; Rehg JE; Russell HR; McKinnon PJ
Nature; 2011 Mar; 471(7337):240-4. PubMed ID: 21390131
[TBL] [Abstract][Full Text] [Related]
9. Alternative Okazaki Fragment Ligation Pathway by DNA Ligase III.
Arakawa H; Iliakis G
Genes (Basel); 2015 Jun; 6(2):385-98. PubMed ID: 26110316
[TBL] [Abstract][Full Text] [Related]
10. DNA ligases I and III cooperate in alternative non-homologous end-joining in vertebrates.
Paul K; Wang M; Mladenov E; Bencsik-Theilen A; Bednar T; Wu W; Arakawa H; Iliakis G
PLoS One; 2013; 8(3):e59505. PubMed ID: 23555685
[TBL] [Abstract][Full Text] [Related]
11. Redundant function of DNA ligase 1 and 3 in alternative end-joining during immunoglobulin class switch recombination.
Masani S; Han L; Meek K; Yu K
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1261-6. PubMed ID: 26787901
[TBL] [Abstract][Full Text] [Related]
12. Human Mre11/human Rad50/Nbs1 and DNA ligase IIIalpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway.
Della-Maria J; Zhou Y; Tsai MS; Kuhnlein J; Carney JP; Paull TT; Tomkinson AE
J Biol Chem; 2011 Sep; 286(39):33845-53. PubMed ID: 21816818
[TBL] [Abstract][Full Text] [Related]
13. Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma.
Newman EA; Lu F; Bashllari D; Wang L; Opipari AW; Castle VP
Mol Cancer Res; 2015 Mar; 13(3):470-82. PubMed ID: 25563294
[TBL] [Abstract][Full Text] [Related]
14. Alternative end-joining catalyzes robust IgH locus deletions and translocations in the combined absence of ligase 4 and Ku70.
Boboila C; Jankovic M; Yan CT; Wang JH; Wesemann DR; Zhang T; Fazeli A; Feldman L; Nussenzweig A; Nussenzweig M; Alt FW
Proc Natl Acad Sci U S A; 2010 Feb; 107(7):3034-9. PubMed ID: 20133803
[TBL] [Abstract][Full Text] [Related]
15. Deficiency of ligase IV leads to reduced NHEJ, accumulation of DNA damage, and can sensitize cells to cancer therapeutics.
Kumari N; Antil H; Kumari S; Raghavan SC
Genomics; 2023 Nov; 115(6):110731. PubMed ID: 37871849
[TBL] [Abstract][Full Text] [Related]
16. Robust chromosomal DNA repair via alternative end-joining in the absence of X-ray repair cross-complementing protein 1 (XRCC1).
Boboila C; Oksenych V; Gostissa M; Wang JH; Zha S; Zhang Y; Chai H; Lee CS; Jankovic M; Saez LM; Nussenzweig MC; McKinnon PJ; Alt FW; Schwer B
Proc Natl Acad Sci U S A; 2012 Feb; 109(7):2473-8. PubMed ID: 22308491
[TBL] [Abstract][Full Text] [Related]
17. Time-dependent predominance of nonhomologous DNA end-joining pathways during embryonic development in mice.
Chiruvella KK; Sebastian R; Sharma S; Karande AA; Choudhary B; Raghavan SC
J Mol Biol; 2012 Mar; 417(3):197-211. PubMed ID: 22306462
[TBL] [Abstract][Full Text] [Related]
18. Structure and function of the DNA ligases encoded by the mammalian LIG3 gene.
Tomkinson AE; Sallmyr A
Gene; 2013 Dec; 531(2):150-7. PubMed ID: 24013086
[TBL] [Abstract][Full Text] [Related]
19. DNA ligase III and DNA ligase IV carry out genetically distinct forms of end joining in human somatic cells.
Oh S; Harvey A; Zimbric J; Wang Y; Nguyen T; Jackson PJ; Hendrickson EA
DNA Repair (Amst); 2014 Sep; 21():97-110. PubMed ID: 24837021
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres.
Badie S; Carlos AR; Folio C; Okamoto K; Bouwman P; Jonkers J; Tarsounas M
EMBO J; 2015 Feb; 34(3):410-24. PubMed ID: 25582120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
